Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Fineline Cube Dec 30, 2025
Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

J&J’s JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma

Fineline Cube Dec 30, 2025
Company Drug

Venus Medtech Completes Patient Enrollment for Liwen RF Ablation System Study

Fineline Cube Mar 6, 2023

China-based Venus Medtech (Hangzhou) Inc. (HKG: 2500) has announced that all patients have been successfully...

Company Deals

PulseCare Raises Pre-Series A Funding for Minimally Invasive Treatment Devices

Fineline Cube Mar 6, 2023

PulseCare, a Shenzhen-based maker of minimally and non-invasive treatment devices, has reportedly raised “tens of...

Company Deals R&D

HKUST and PhIRDA Sign MoU to Establish Innovation Centers

Fineline Cube Mar 4, 2023

The Hong Kong University of Science and Technology (HKUST) and the China Pharmaceutical Innovation and...

Policy / Regulatory

China Releases Blue Book on Medical Insurance Fund Supervision

Fineline Cube Mar 3, 2023

The China Health Insurance and Social Sciences Academic Press has jointly released the “Blue Book...

Policy / Regulatory

NHC Recommends Simcere and Junshi COVID-19 Therapies in Updated Guidelines

Fineline Cube Mar 3, 2023

The National Health Commission (NHC) has released a notification including Simcere Pharmaceutical Group’s (HKG: 2096)...

Company Deals

ClinChoice Acquires Cromsource to Expand Global CRO Footprint

Fineline Cube Mar 3, 2023

Sino-US Contract Research Organization (CRO) ClinChoice Medical Development has announced the acquisition of Cromsource S.r.l.,...

Company Drug

Atom Bioscience’s ABP-671 Shows Positive Phase IIa Results in Gout Treatment

Fineline Cube Mar 3, 2023

China-based Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd) has announced positive results from...

Company Deals

Echo Biotech Secures Series A++ Funding for Exosomes Drug Development

Fineline Cube Mar 3, 2023

Echo Biotech, a Beijing-based exosomes drug developer, has reportedly raised “tens of millions” of renminbi...

Company Medical Device

AffaMed Technologies Completes First Patient Implantation for MINI WELL IOL

Fineline Cube Mar 3, 2023

AffaMed Technologies, a joint venture between AffaMed Therapeutics and SIFI S.p.A., has announced the completion...

Company Drug

CSPC Pharmaceutical Initiates Phase III Study for Mitoxantrone Liposome in Nasopharyngeal Carcinoma

Fineline Cube Mar 3, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced the first patient dosing in a...

Policy / Regulatory

National VBP Tender Round 8 to Be Held in Hainan with 40 Drugs Bidding

Fineline Cube Mar 3, 2023

The National Allied Procurement Office has released a notification regarding the Round 8 of the...

Company Deals

TinKer Bio Raises Series A+ Funding for Microfluidic Chip Expansion

Fineline Cube Mar 3, 2023

China-based Hangzhou TinKer BioTechnology Co., Ltd, a leading microfluidic chip technology platform company, has reportedly...

Company Drug

OcuMension Therapeutics Initiates Phase II Study for Dry Eye Treatment OT-202

Fineline Cube Mar 3, 2023

Chinese ophthalmology specialist OcuMension Therapeutics (HKG: 1477) has announced the initiation of a randomized, double-blind,...

Company Deals

Hexin Medical Technology Raises Series A Funding for Radionuclide Therapy

Fineline Cube Mar 3, 2023

Hexin Medical Technology Co., Ltd, a radionuclide therapy developer based in Suzhou, has reportedly raised...

Company Deals

Shanghai Pharmaceuticals Partners with Baiyun District for Health Initiative

Fineline Cube Mar 3, 2023

China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has entered into a strategic cooperation agreement...

Company Deals

TandemAI Secures $35M Series A to Expand Drug Discovery Platform

Fineline Cube Mar 3, 2023

TandemAI, a technology firm with operations in New York, San Diego, and China, has successfully...

Company Drug

Merck Reports 12.9% Sales Growth in 2022 Annual Report

Fineline Cube Mar 3, 2023

German major Merck (NYSE: MRK) released its 2022 annual report this week, showing a robust...

Policy / Regulatory

NHSA Releases Guidelines on Drug Procurement and Pricing Management

Fineline Cube Mar 2, 2023

The National Healthcare Security Administration (NHSA) has released a notification regarding provincial centralized procurement and...

Company Deals

Kinnjiu Biopharma Initiates Global Phase I Study for Exarafenib

Fineline Cube Mar 2, 2023

Shanghai-based Kinnjiu Biopharma Inc. has announced the first subject dosing in the global multi-center Phase...

Company

Zai Lab Reports 2022 Financial Results with Revenue Growth

Fineline Cube Mar 2, 2023

China-based Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) has announced its full-year 2022 financial results,...

Posts pagination

1 … 492 493 494 … 602

Recent updates

  • J&J’s JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial
  • HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma
  • Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug
  • Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma
  • Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

J&J’s JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial

Company Drug

HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma

Company Deals

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Company Drug

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.